Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177814
First received: September 13, 2005
Last updated: June 17, 2013
Last verified: June 2013
  Purpose

The proposed endpoints of the study would be: comparative use of piperacillin versus broader spectrum agents (e.g., piperacillin/tazobactam, etc.) [measured as defined daily doses per 1000 patient days]; physician acceptance of piperacillin as part of a streamlining program [measured as successful occurrences of the use of piperacillin as streamlining therapy]; changes in susceptibility patterns of broad spectrum antibiotics [measured as % Gram negative bacilli susceptible to each of the commonly used broad spectrum antibiotics]; and outcome of patients treated with streamlined therapy.


Condition
Gram-negative Bacterial Infections

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Estimated Enrollment: 1000
Study Start Date: September 2005
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Detailed Description:

The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, recent immunomodulative therapies, physical exam findings, laboratory and radiographical data, antimicrobial usage, microbiological data and resistance patterns, choice of antibiotics once organism is identified, suspected source of infection, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome, gender, height, weight, ethnicity, and past medical history.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients treated with piperacillin/tazobactam and or piperacillin

Criteria

Inclusion Criteria:

  • Patients with Gram negative infections treated with piperacillin/tazobactam and/or piperacillin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00177814

Locations
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Celgene Corporation
Investigators
Principal Investigator: David Paterson, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00177814     History of Changes
Other Study ID Numbers: IRB # 0508074
Study First Received: September 13, 2005
Last Updated: June 17, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
pipercillin
gram negative bacteria infections

Additional relevant MeSH terms:
Bacterial Infections
Gram-Negative Bacterial Infections
Anti-Bacterial Agents
Piperacillin
Antibiotics, Antitubercular
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents

ClinicalTrials.gov processed this record on August 21, 2014